The present invention relates to novel chlorotonil derivatives of formula (I) and the use thereof for the treatment or prophylaxis of bacterial infections and malaria. ##STR00001##

The invention provides a method of isolating one or more compounds present in fruit juice or seed extracts that have anti-microbial activity.

The invention provides a method of isolating one or more compounds present in fruit juice or seed extracts that have anti-microbial activity.

Cyclic amino-pyrazinecarboxamide compounds, salts, and pharmaceutical compositions for use in the treatment of disease, such as cancer, are disclosed herein. The disclosed compounds are useful, among other things, in the treating of disease, for example cancer and/or fibrotic diseases, and modulating TGFβR2.

An 8-dihalomethyl berberine-type quaternary ammonium salt compound represented by general formula (I) or (II) and an application thereof in preparing a drug. The compound shows hydrophilicity and has antimicrobial, anti-inflammatory, anti-ulcerative colitis, and antitumor activities, while having no or low toxicity. ##STR00001##

An 8-dihalomethyl berberine-type quaternary ammonium salt compound represented by general formula (I) or (II) and an application thereof in preparing a drug. The compound shows hydrophilicity and has antimicrobial, anti-inflammatory, anti-ulcerative colitis, and antitumor activities, while having no or low toxicity. ##STR00001##

The present disclosure provides, inter alia, scaffolds and compounds having the structure:

##STR00001##

Also provided are compositions containing a pharmaceutically acceptable carrier and one or more compounds according to the present disclosure. Further provided are methods for treating or ameliorating the effects of a cancer in a subject, methods for selectively killing a cancer cell, methods of modulating mTORC1/2 signaling activity in a cell, methods of modulating the activity of a Master Regulator for MycN in a subject having MycN-amplified neuroblastoma (MycN.sup.AMP NBL), methods of selectively treating or ameliorating effects of a cancer in a subject in need thereof, and platforms and methods for identifying a compound that induces degradation of a cancer-related protein. Also provided are kits comprising a compound or a pharmaceutical composition according to the present disclosure. Methods for treating cancers and methods for modulating MYC Master Regulators using other compounds are also provided.

The present disclosure provides, inter alia, scaffolds and compounds having the structure:

##STR00001##

Also provided are compositions containing a pharmaceutically acceptable carrier and one or more compounds according to the present disclosure. Further provided are methods for treating or ameliorating the effects of a cancer in a subject, methods for selectively killing a cancer cell, methods of modulating mTORC1/2 signaling activity in a cell, methods of modulating the activity of a Master Regulator for MycN in a subject having MycN-amplified neuroblastoma (MycN.sup.AMP NBL), methods of selectively treating or ameliorating effects of a cancer in a subject in need thereof, and platforms and methods for identifying a compound that induces degradation of a cancer-related protein. Also provided are kits comprising a compound or a pharmaceutical composition according to the present disclosure. Methods for treating cancers and methods for modulating MYC Master Regulators using other compounds are also provided.

A novel organic compound is provided. Alternatively, an organic compound that emits light with favorable chromaticity is provided. Alternatively, an organic compound that emits blue light with favorable chromaticity is provided. Alternatively, a light-emitting element with favorable emission efficiency is provided. Alternatively, an organic compound with an excellent carrier-transport property is provided. The organic compound includes any of a substituted or unsubstituted dibenzofurobisbenzofuran skeleton, a substituted or unsubstituted dibenzothienobisbenzothiophene skeleton, a substituted or unsubstituted benzobisbenzothienobenzofuran skeleton, and a substituted or unsubstituted dibenzothienobisbenzofuran skeleton and one or two amino groups. In the organic compound, the amino group includes a substituted or unsubstituted heteroaryl group and any of a substituted or unsubstituted aromatic hydrocarbon group having 6 to 25 carbon atoms and a substituted or unsubstituted heteroaryl group having 5 to 25 carbon atoms.

A novel organic compound is provided. Alternatively, an organic compound that emits light with favorable chromaticity is provided. Alternatively, an organic compound that emits blue light with favorable chromaticity is provided. Alternatively, a light-emitting element with favorable emission efficiency is provided. Alternatively, an organic compound with an excellent carrier-transport property is provided. The organic compound includes any of a substituted or unsubstituted dibenzofurobisbenzofuran skeleton, a substituted or unsubstituted dibenzothienobisbenzothiophene skeleton, a substituted or unsubstituted benzobisbenzothienobenzofuran skeleton, and a substituted or unsubstituted dibenzothienobisbenzofuran skeleton and one or two amino groups. In the organic compound, the amino group includes a substituted or unsubstituted heteroaryl group and any of a substituted or unsubstituted aromatic hydrocarbon group having 6 to 25 carbon atoms and a substituted or unsubstituted heteroaryl group having 5 to 25 carbon atoms.